Beijing, China - Shanghai MicroPort Medical (Group) Co ("MicroPort®") recently attended China Heart Congress 2015 ("CHC 2015") held from August 6 to August 8. More than 7,500 experts and scholars from cardiovascular related fields came to the conference. MicroPort® held a satellite meeting during the conference to promote the in-house developed third generation Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"). During the satellite meeting, MicroPort® shared the four-year follow-up data of Firehawk® TARGET I clinical studies to the experts in attendance.
The MicroPort® satellite meeting was held on August 8. Professor Shubin Qiao from Fuwai Hospital, Professor Lang Li from The First Affiliated Hospital of Guangxi Medical University, Professor Guizhou Tao from The First Affiliated Hospital of Liaoning Medical University and Professor Xuebo Liu from Shanghai East Hospital were invited as presidents of the satellite meeting. Professor Bo Xu from Fuwai Hospital, Professor Xiaohua Ying from Public Health School of Fudan University, Professor Yue Li from The First Affiliated Hospital of Harbin Medical University and Professor Wei Guo from Shuguang Hospital, introduced Firehawk®'s features, shared its clinical trial results, reported health economic evaluation of Firehawk® and shared case review of Firehawk® at the satellite meeting.
Professor Bo Xu analyzed the four-year follow-up data of Firehawk® TARGET I clinical study, and reached two conclusions: Firstly, the data show that the TLF of the Firehawk® group and the Xience V group were 4.5% and 6.3% respectively, and there was only one additional case of Target Lesion Revascularization in the Firehawk® group while six cases were found in the Xience V group. Firehawk® has the same efficacy as Xience V stent with only 1/2 drug dosage compared to Xience V stent. But Firehawk® was proved to be safer as in the Firehawk® group the rate of myocardial infarction in the target vessel did not increase and the incidence rate of stent thrombosis remained zero, while in the Xience V group one possible stent thrombosis occurred in the four-year clinical study, with 0.4% incidence rate. Secondly, the four-year follow-up results of the TARGET I long stent group showed TLF stood at 10.6%, no cardiac death occurred, two cases of myocardial infarction and three cases of iTLR occurred during the preoperative period, and no thrombosis occurred, which proved Firehawk®'s safety in long lesions. Professor Bo Xu spoke highly of Firehawk®'s safety and efficacy, and his report helped enhance attendees' understanding in the product.
Professor Xiaohua Ying interpreted the health economic evaluation report of Firehawk® at the satellite meeting. By comparing the prices and economic benefits of Firehawk® and Xience V, the report proved that Firehawk® is more cost-effective than Xience V in treating single coronary artery lesion in single vessel. It showed Firehawk®'s advantages and promising future prospects.
During the conference, MicroPort® also carried out satisfaction survey activities, and communicated with relevant experts about current coronary products, development trend of products under research, and how MicroPort® will provide follow-up service. Experts showed high recognition of MicroPort® products' perfect quality and good performances in clinical surgeries.
As cardiovascular industry's most influential academic event of cardiovascular diseases in China and the Asia-Pacific region, CHC 2015, themed "healthy heart, a better life - innovation, translation and cooperation," displayed new achievements in clinical prevention and basic research of cardiovascular diseases, introduced new developments in translational medical research, explored the future trend of integrated medicine and individualized treatment, prevention and research, so as to further promote the development of cardiology in China.